Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 26;25(1):1153.
doi: 10.1186/s12889-025-22311-4.

A cross-sectional survey of COVID-19 testing status among vaccine recipients in Gombe State, North-Eastern Nigeria

Affiliations

A cross-sectional survey of COVID-19 testing status among vaccine recipients in Gombe State, North-Eastern Nigeria

Nafisah Ayinde Sikiru et al. BMC Public Health. .

Abstract

The COVID-19 testing status and vaccine acceptance are two key components of any COVID-19 control program as they are important in evaluating the prevalence of the disease as well as curbing the spread of the SARS-CoV-2, the causative agent of COVID-19. Hence, the aim of this study was to conduct a non-probability cross-sectional survey of COVID-19 vaccine recipients in Gombe State to determine their testing status and socio-demographic profiles. A total of 872 vaccine recipients were included in this study. The descriptive analysis revealed that the median age group was 30-39 years. More than half (57.7%, n = 503) of the study participants earned 50,000 Naira or less and approximately 51% of the vaccine recipients (n = 444) had tertiary education. Approximately one-third (35.1%, n = 306/872) of the study participants have been previously screened for SARS-CoV-2 and the COVID-19 positivity rate among them was 6.9% (n = 21/306). Some 108 (18.2%) persons reported Adverse Event Following Immunization (AEFI). The multivariable logistic regression analysis revealed that the age [30-39 years, (OR: 1.76; 95% CI: 1.13, 2.74; p = 0.041)], monthly income [150,000 naira and above (OR: 10.43; 95% CI: 2.22, 21.88; p < 0.001)], and background [health-related, (OR: 6.30; 95% CI: 4.35, 9.13; p = 0.01)] of the vaccine recipients was significantly associated with the COVID-19 testing status. The COVID-19 testing status of vaccine recipients is low. Hence, mass COVID-19 screening strategies should be implemented together with improved vaccine advocacy to focus on vaccine safety and efficacy.

Keywords: COVID-19; COVID-19 testing, Nigeria; Socio- demographic; Vaccine acceptance.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: we got ethical approval from Gombe State of Nigeria, Ministry of Health Headquarters with reference MOH/ADM/621/S/456. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The testing status of COVID-19 vaccine recipients in Gombe State (n = 872)

Similar articles

References

    1. Okereke M, Ukor NA, Adebisi YA, Ogunkola IO, Favour Iyagbaye E, Adiela Owhor G, Lucero-Prisno DE III. Impact of COVID‐19 on access to healthcare in low‐and middle‐income countries: current evidence and future recommendations. Int J Health Plann Manag. 2021;36(1):13–7. - PubMed
    1. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020;19(1):1–6. - PMC - PubMed
    1. Worldometer COVID. Live - Coronavirus Statistics - Worldometer [Internet]. Worldometers.info. 2022 [cited 26 September 2022]. Available from: https://www.worldometers.info/coronavirus/. Accessed 26 September 2022.
    1. Coronavirus NCDCNCDC. COVID-19 Microsite [Internet]. Covid19.ncdc.gov.ng. 2022 [cited 26 September 2022]. Available from: https://covid19.ncdc.gov.ng/. Accessed 26 September 2022.
    1. Al-Mustapha AI, Tijani AA, Oyewo M, Ibrahim A, Elelu N, Ogundijo OA. Nigeria’s race to zero COVID-19 cases: true disease burden or testing failure? J Global Health. 2021;11. - PMC - PubMed

Substances